成都柏奥特克生物科技

Bio-Therapeutic Biotech is a clinical-stage biotechnology company headquartered in Chengdu, China, dedicated to the development of next-generation recombinant vaccines. The company leverages its proprietary recombinant protein expression and novel adjuvant technology platforms to create vaccines for infectious diseases with high unmet medical needs. Its lead program is a recombinant herpes zoster vaccine, which is currently in Phase 2 clinical trials and aims to provide a high-efficacy alternative to existing shingles vaccines. Beyond shingles, the company's pipeline includes candidates for HPV, rabies, and rotavirus, all utilizing recombinant technology to improve safety and immunogenicity. Bio-Therapeutic Biotech operates integrated R&D and large-scale GMP manufacturing facilities within the Chengdu Tianfu International Bio-Town. The company has secured significant backing from prominent investors like CD Capital and Oriza Holdings to accelerate its clinical programs and commercialization strategy.